Eli Lilly and Company (NYSE:LLY), a US-based pharmaceutical company, announced on Friday that it has named Mary Lynne Hedley, PhD as its new director effective 15 May 2022.
Dr Hedley is to serve both the Science & Technology Committee and the Ethics and Compliance Committee.
Dr Hedley is an immunologist and cancer cell biologist and has served as a senior scientific fellow at the Broad Institute of MIT and Harvard. She has also worked as director, president, and chief operating officer at TESARO, Inc, and has served as executive vice president and chief science officer of Abraxis Bioscience, Inc.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer